Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 12/2012

01-12-2012 | Letter to the Editor

Recurrent superior vena cava syndrome caused by IgD multiple myeloma

Authors: L. Farnault, S. Chebrek, P. Souteyrand, G. Sebahoun, Regis Costello

Published in: Annals of Hematology | Issue 12/2012

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W (1975) IgD multiple myeloma. Review of 133 cases. Arch Intern Med 135:87–93PubMedCrossRef
2.
Hobbs JR, Corbett AA (1969) Younger age of presentation and extraosseous tumour in IgD myelomatosis. Br Med J 1:412–414PubMedCrossRef
3.
Shimamoto Y, Anami Y, Yamaguchi M (1991) A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol 47:262–267PubMedCrossRef
4.
Blade J, Lust JA, Kyle RA (1994) Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol: Off J Am Soc Clin Oncol 12:2398–2404
5.
Kim MK, Suh C, Lee DH et al (2011) Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 22:411–416CrossRef
6.
San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917PubMedCrossRef
7.
Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia: Off J Leuk Soc Am Leuk Res Fund UK 23:3–9CrossRef
Metadata
Title
Recurrent superior vena cava syndrome caused by IgD multiple myeloma
Authors
L. Farnault
S. Chebrek
P. Souteyrand
G. Sebahoun
Regis Costello
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 12/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1496-0

Other articles of this Issue 12/2012

Annals of Hematology 12/2012 Go to the issue

Original Article

Excellent long-term survival of 170 patients with Waldenström’s macroglobulinemia treated in private oncology practices and a university hospital

Original Article

Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients

Original Article

Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival

Original Article

Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation

Letter to the Editor

Central nervous system involvement of primary cutaneous diffuse large B cell lymphoma-leg type diagnosed according to the WHO 2008 classification

Original Article

Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits